Scopus
YÖKSİS Eşleşti
Efficacy comparison of oral rosuvastatin versus oral progesterone and bevacizumab on regression of surgically endometriotic implants in rats
Gynecological Endocrinology · Aralık 2017
YÖKSİS Kayıtları
Efficacy comparison of oral rosuvastatin versus oral progesterone and bevacizumab on regression of surgically endometriotic implants in rats
Gynecological Endocrinology · 2017 SCI-Expanded
DOKTOR ÖĞRETİM ÜYESİ DUYGU DURSUNOĞLU →
Efficacy comparison of oral rosuvastatin versus oral progesterone and bevacizumab on regression of surgically endometriotic implants in rats.
Gynecological endocrinology · 2017 SCI-Expanded
PROFESÖR SÜLEYMAN BALDANE →
Efficacy comparison of oral rosuvastatin versus oral progesterone and bevacizumab on regression of surgically endometriotic implants in rats
Gynecological Endocrinology · 2017 SCI-Expanded
PROFESÖR ÇETİN ÇELİK →
Efficacy comparison of oral rosuvastatin versus oral progesterone and bevacizumab on regression of surgically endometriotic implants in rats
Gynecological Endocrinology · 2017 SCI-Expanded
PROFESÖR MUSTAFA GAZİ UÇAR →
Makale Bilgileri
DergiGynecological Endocrinology
Yayın TarihiAralık 2017
Cilt / Sayfa33 · 923-927
Scopus ID2-s2.0-85018158117
Özet
This study hypothesizes that oral rosuvastatin, oral dienogest and intraperitoneal bevacizumab might improve endometriosis in randomly selected female Wistar albino rats with surgically endometriotic implants. Thirty female Wistar albino rats with surgically endometriotic implants were randomized into three treatment groups: oral rosuvastatin (20 mg kg/day; oral rosuvastatin group 1; n = 10), oral progesterone (dienogest group 2; n = 10) and intraperitoneal bevacizumab (2.5 mg/kg of single intraperitoneal injection of bevacizumab; bevacizumab group 3; n = 10), for 10 days. Post-treatment variables were compared. The oral rosuvastatin group showed higher reduction for the glandular epithelium and uterine vessels of histopathological scores values than the oral progesterone group (both, p < 0.017, respectively). The median glandular epithelium and uterine vessels and histopathological scores values did not show a statistically significant difference between group 1 and group 3 (p > 0.017). Endometrial thickness values and uterine volume values were more significantly reduced in the oral rosuvastatin group than the oral progesterone group (both, p < 0.017, respectively). Moreover, endometrial thickness and uterine volume values were not different in groups wecompared with group 3 (p > 0.017). In conclusion, oral rosuvastatin and intraperitoneal injection of bevacizumab may cause more significant regression of surgically endometriotic implants in rats than oral progesterone medications.
Yazarlar (10)
1
Ayşe Gül Kebapçilar
2
Tolgay Tuyan İlhan
3
Duygu Dursunoǧlu
ORCID: 0000-0003-4414-8659
4
Levent Kebapcilar
5
Suleyman Hilmi Ipekci
ORCID: 0000-0003-4410-2212
6
Süleyman Baldane
7
Mustafa Gazi Uçar
8
Cem Onur Kirac
9
Kubra Kurt
10
Çetin Çelik
ORCID: 0000-0001-6165-5092
Anahtar Kelimeler
Bevacizumab
endometriotic implants
oral progesterone
oral rosuvastatin
Kurumlar
Selçuk Üniversitesi
Selçuklu Turkey
Metrikler
8
Atıf
10
Yazar
4
Anahtar Kelime